Hot Features
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of so... Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.13 | -3.72492836676 | 3.49 | 3.505 | 3.34 | 21457 | 3.44065154 | CS |
| 4 | 0.11 | 3.38461538462 | 3.25 | 4.04 | 3.1 | 225954 | 3.43402508 | CS |
| 12 | -1.65 | -32.9341317365 | 5.01 | 5.03 | 2.75 | 120186 | 3.5428361 | CS |
| 26 | 1.35 | 67.1641791045 | 2.01 | 5.07 | 1.81 | 140795 | 3.91513442 | CS |
| 52 | 0.84 | 33.3333333333 | 2.52 | 5.07 | 1.81 | 95815 | 3.52161454 | CS |
| 156 | -0.52 | -13.4020618557 | 3.88 | 5.07 | 1.81 | 44975 | 3.33501792 | CS |
| 260 | -5.44 | -61.8181818182 | 8.8 | 9.38 | 1.81 | 41676 | 3.54155591 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.